SCP-8883
Euclid
~
medium confidence
SCP-8883
Expected annual
$15.8M
One-time setup
$30.3M
Annual recurring
$15.6M
Personnel
59
One-time establishment costs are roughly $30.3M driven by contingency reserves, vendor compromise, cyber‑operations, R&D and clinic setup; ongoing annual costs are roughly $15.6M driven primarily by 24/7 monitoring staff, R&D/maintenance of detection infrastructure, amnestic administration and legal/cover operations.
One-Time Capital Costs
Total: $30.3M
Annual Recurring Costs
Total: $15.6M/yr
Cost Scenarios
📊
Baseline
(baseline)
$15.6M/yr
Normal year with ongoing detection, monitoring, R&D and routine interventions; no major public exposures or large government actions.
routine_detections
no_major_exposure
normal_operational_load
🚨
Minor Incident
$15.9M/yr
Several local incidents requiring additional physical interventions, travel and emergency caseloads but no wide public exposure.
multiple_physical_interventions
regional_media_attention
spike_in_emergency_cases
🚨
Major Exposure
$18.6M/yr
A high‑profile public exposure or cluster that forces substantial scale‑up of amnestic/treatment operations and legal/PR spending.
high_profile_media_exposure
large_cluster
international_attention
🚨
Government Inquiry
$25.6M/yr
Major government investigation or international scrutiny requiring deployment of contingency war chest, legal action, asset acquisition, and emergency mass operations.
government_investigation
mass_media_exposé
regulatory_official_action
Personnel
59 total
| Role | Count | Notes |
|---|---|---|
| Radiology Analyst / Incident Controller | 40 | [#4] 24/7 detection review, triage, false‑positive filtering and incident coordination (matches monitoring staff wages portion). |
| Mobile Medical Team (Undercover Doctor / Field Agent) | 10 | [#5] Staffing for regional covert treatment teams (recurring staffing budget portion). |
| Epidemiologist / Data Scientist | 6 | [#9] Surveillance, incidence tracking, modelling and liaison with public health agencies. |
| Senior Medical Officer | 3 | [#4] Senior decision makers for high‑profile case classification and anomalous treatment authorization. |
Confidence Notes
Line items and cost ranges are well described in analyst notes, but large uncertainties remain around incident frequency, vendor negotiation scope, and R&D success horizon; resulting totals are moderate‑confidence estimates.